{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:38:45Z","timestamp":1794407925452,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC (MFAG 27415)"],"award-info":[{"award-number":["AIRC (MFAG 27415)"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC Accelerator Grant PREDICT MESO (ID24290)"],"award-info":[{"award-number":["AIRC Accelerator Grant PREDICT MESO (ID24290)"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Epigen 2"],"award-info":[{"award-number":["Epigen 2"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pleural mesothelioma (PM) is an aggressive cancer that originates from mesothelial cells lining the pleura. To identify the different cell types in mesothelioma and their relationships, we performed single-cell RNAseq analyses of non-malignant pleura biopsies, PM biopsies and PM patient-derived organoids. Gene expression profiles of mesothelial and mesothelioma cells are very similar, suggesting that mesothelioma cells retain most properties of mesothelial cells. Surprisingly, in PM patient-derived organoids mesothelioma cells can acquire a fibroblast-like gene expression profile. Indeed, in most of the original PM biopsies a fraction of cells within the cluster of cancer-associated fibroblasts (CAFs) appear derived from tumor cells, with which they share the same genomic rearrangements. We confirmed by immunohistochemistry, and thus at the protein level, that cancer-derived fibroblast-like cells (CDFs) express smooth muscle actin, as most CAFs do, but have lost the same tumor suppressor proteins as the cognate mesothelioma cells. We propose that mesothelioma cells can become CDFs because they retain the ability of mesothelial cells to differentiate into fibroblasts. CDFs are thus tumor cells with fibroblast-like gene expression associated to tumors, and fulfil the definition of CAFs. CAFs generally support tumor progression, and in most tumors derive from resident fibroblasts or circulating mesenchymal cells. Our finding that a subset of CAFs derive from tumor cells, at least in mesothelioma, challenges current understanding of CAF origin. We suggest that interfering with the mesothelioma-to-CAF transition might offer an avenue to moderate tumor progression and resistance to therapy.<\/jats:p>","DOI":"10.1038\/s41418-025-01639-9","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:15:05Z","timestamp":1765901705000},"page":"1203-1217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fibroblast-like cells in mesothelioma can derive from tumor cells"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-040X","authenticated-orcid":false,"given":"Jose M.","family":"Garcia-Manteiga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltjona","family":"Rrapaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-8157","authenticated-orcid":false,"given":"Francesca","family":"Caprioglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Marchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam S.","family":"Colley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Carretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mercalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Molinario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Arrigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Boldorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-9670","authenticated-orcid":false,"given":"Massimo P.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1271-8998","authenticated-orcid":false,"given":"Rosanna","family":"Mezzapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5329-6445","authenticated-orcid":false,"given":"Marco E.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"1639_CR1","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1183\/09031936.98.12040972","volume":"12","author":"C Boutin","year":"1998","unstructured":"Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J. 1998;12:972\u201381.","journal-title":"Eur Respir J"},{"key":"1639_CR2","unstructured":"WHO Classification of Tumours, Thoracic Tumours, 5th edn. International Agency for Research on Cancer; 2020."},{"key":"1639_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668\u201372.","journal-title":"Nat Genet"},{"key":"1639_CR4","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/bjc.2013.130","volume":"108","author":"R Mezzapelle","year":"2013","unstructured":"Mezzapelle R, Miglio U, Rena O, Paganotti A, Allegrini S, Antona J, et al. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. Br J Cancer. 2013;108:1743\u20139.","journal-title":"Br J Cancer"},{"key":"1639_CR5","first-page":"491","volume":"1","author":"BM Robinson","year":"2012","unstructured":"Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1:491\u20136.","journal-title":"Ann Cardiothorac Surg"},{"key":"1639_CR6","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1073\/pnas.1006542107","volume":"107","author":"H Yang","year":"2010","unstructured":"Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA. 2010;107:12611\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1639_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307999120","volume":"120","author":"JS Suarez","year":"2023","unstructured":"Suarez JS, Novelli F, Goto K, Ehara M, Steele M, Kim JH, et al. HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma. Proc Natl Acad Sci USA. 2023;120:e2307999120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1639_CR8","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","volume":"14","author":"B Giotti","year":"2024","unstructured":"Giotti B, Dolasia K, Zhao W, Cai P, Sweeney R, Merritt E, et al. Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma. Cancer Discov. 2024;14:2262\u201378.","journal-title":"Cancer Discov"},{"key":"1639_CR9","doi-asserted-by":"crossref","unstructured":"Mutsaers SE, Wilkosz S. Structure and function of mesothelial cells. In: Peritoneal Carcinomatosis. Springer US: Boston, MA, pp 1\u201319.","DOI":"10.1007\/978-0-387-48993-3_1"},{"key":"1639_CR10","first-page":"eColletion 2014","volume":"284","author":"H Batra","year":"2014","unstructured":"Batra H, Antony VB. The pleural mesothelium in development and disease. Front Physiol. 2014;284:eColletion 2014.","journal-title":"Front Physiol"},{"key":"1639_CR11","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1111\/j.1582-4934.2010.01212.x","volume":"15","author":"SM Lansley","year":"2011","unstructured":"Lansley SM, Searles RG, Hoi A, Thomas C, Moneta H, Herrick SE, et al. Mesothelial cell differentiation into osteoblast- and adipocyte-like cells. J Cell Mol Med. 2011;15:2095\u2013105.","journal-title":"J Cell Mol Med"},{"key":"1639_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3747\/pdi.2014.00188","volume":"35","author":"Y Liu","year":"2015","unstructured":"Liu Y, Dong Z, Liu H, Zhu J, Liu F, Chen G. Transition of Mesothelial Cell to Fibroblast in Peritoneal Dialysis: EMT, Stem Cell or Bystander?. Perit Dial Int. 2015;35:14\u201325.","journal-title":"Perit Dial Int"},{"key":"1639_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphar.2015.00113","volume":"6","author":"SE Mutsaers","year":"2015","unstructured":"Mutsaers SE, Birnie K, Lansley S, Herrick SE, Lim C-B, Prele CM. Mesothelial cells in tissue repair and fibrosis. Front Pharm. 2015;6:113 eCollection 2015.","journal-title":"Front Pharm"},{"key":"1639_CR14","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1046\/j.1523-1755.2003.00861.x","volume":"63","author":"AH Yang","year":"2003","unstructured":"Yang AH, Chen JY, Lin JK. Myofibroblastic conversion of mesothelial cells. Kidney Int. 2003;63:1530\u20139.","journal-title":"Kidney Int"},{"key":"1639_CR15","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55:1322\u201332.","journal-title":"Exp Mol Med"},{"key":"1639_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06240-x","volume":"14","author":"Y Chrisochoidou","year":"2023","unstructured":"Chrisochoidou Y, Roy R, Farahmand P, Gonzalez G, Doig J, Krasny L, et al. Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells. Cell Death Dis. 2023;14:725.","journal-title":"Cell Death Dis"},{"key":"1639_CR17","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.ajpath.2011.05.060","volume":"179","author":"Q Li","year":"2011","unstructured":"Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, et al. Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts to Promote Progression via a Malignant Cytokine Network. Am J Pathol. 2011;179:1483\u201393.","journal-title":"Am J Pathol"},{"key":"1639_CR18","doi-asserted-by":"publisher","first-page":"12426","DOI":"10.3390\/ijms241512426","volume":"24","author":"S Borchert","year":"2023","unstructured":"Borchert S, Mathilakathu A, Nath A, Wessolly M, Mairinger E, Kreidt D, et al. Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model. Int J Mol Sci. 2023;24:12426.","journal-title":"Int J Mol Sci"},{"key":"1639_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/modpathol.3880018","volume":"13","author":"PM Cury","year":"2000","unstructured":"Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG. Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5\/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura. Mod Pathol. 2000;13:107\u201312.","journal-title":"Mod Pathol"},{"key":"1639_CR20","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022\u20135.","journal-title":"Nat Genet"},{"key":"1639_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","volume":"33","author":"DB Chapel","year":"2020","unstructured":"Chapel DB, Schulte JJ, Berg K, Churg A, Dacic S, Fitzpatrick C, et al. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod Pathol. 2020;33:245\u201354.","journal-title":"Mod Pathol"},{"key":"1639_CR22","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","volume":"66","author":"F Lo\u0301pez-Ri\u0301os","year":"2006","unstructured":"Lo\u0301pez-Ri\u0301os F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16\/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. Cancer Res. 2006;66:2970\u20139.","journal-title":"Cancer Res"},{"key":"1639_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/cancers15030641","volume":"15","author":"NB Palstr\u00f8m","year":"2023","unstructured":"Palstr\u00f8m NB, Overgaard M, Licht P, Beck HC. Identification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics. Cancers. 2023;15:641.","journal-title":"Cancers"},{"key":"1639_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41587-022-01468-y","volume":"41","author":"T Gao","year":"2023","unstructured":"Gao T, Soldatov R, Sarkar H, Kurkiewicz A, Biederstedt E, Loh P-R, et al. Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes. Nat Biotechnol. 2023;41:417\u201326.","journal-title":"Nat Biotechnol"},{"key":"1639_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22397-5","volume":"12","author":"CQE Lee","year":"2021","unstructured":"Lee CQE, Kerouanton B, Chothani S, Zhang S, Chen Y, Mantri CK, et al. Coding and non-coding roles of MOCCI (C15ORF48) coordinate to regulate host inflammation and immunity. Nat Commun. 2021;12:2130.","journal-title":"Nat Commun"},{"key":"1639_CR26","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","volume":"110","author":"S Zhou","year":"2014","unstructured":"Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, et al. Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma. Br J Cancer. 2014;110:2479\u201388.","journal-title":"Br J Cancer"},{"key":"1639_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s10637-021-01086-6","volume":"39","author":"MG Zauderer","year":"2021","unstructured":"Zauderer MG, Alley EW, Bendell J, Capelletto E, Bauer TM, Callies S, et al. Phase 1 cohort expansion study of LY3023414, a dual PI3K\/mTOR inhibitor, in patients with advanced mesothelioma. Invest N Drugs. 2021;39:1081\u20138.","journal-title":"Invest N Drugs"},{"key":"1639_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.omtn.2021.04.001","volume":"24","author":"A Singh","year":"2021","unstructured":"Singh A, Pruett N, Pahwa R, Mahajan AP, Schrump DS, Hoang CD. MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis. Mol Ther Nucleic Acids. 2021;24:669\u201381.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1639_CR29","doi-asserted-by":"publisher","first-page":"2300143","DOI":"10.1183\/13993003.00143-2023","volume":"63","author":"J Obacz","year":"2024","unstructured":"Obacz J, Valer JA, Nibhani R, Adams TS, Schupp JC, Veale N, et al. Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma. Eur Respir J. 2024;63:2300143.","journal-title":"Eur Respir J"},{"key":"1639_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"1639_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y, et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc. 2016;11:347\u201358.","journal-title":"Nat Protoc"},{"key":"1639_CR32","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9:1102\u201323.","journal-title":"Cancer Discov"},{"key":"1639_CR33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40:656\u201373.e7.","journal-title":"Cancer Cell"},{"key":"1639_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/path.4281","volume":"231","author":"P Sandoval","year":"2013","unstructured":"Sandoval P, Jim\u00e9nez-Heffernan JA, Rynne-Vidal \u00c1, P\u00e9rez-Lozano ML, Gilsanz \u00c1, Ruiz-Carpio V, et al. Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis. J Pathol. 2013;231:517\u201331.","journal-title":"J Pathol"},{"key":"1639_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/cancers12020499","volume":"12","author":"CH Gordillo","year":"2020","unstructured":"Gordillo CH, Sandoval P, Mu\u00f1oz-Hern\u00e1ndez P, Pascual-Ant\u00f3n L, L\u00f3pez-Cabrera M, Jim\u00e9nez-Heffernan JA. Mesothelial-to-Mesenchymal Transition Contributes to the Generation of Carcinoma-Associated Fibroblasts in Locally Advanced Primary Colorectal Carcinomas. Cancers. 2020;12:499.","journal-title":"Cancers"},{"key":"1639_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021;1:e90.","journal-title":"Curr Protoc"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01639-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:15:22Z","timestamp":1780931722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01639-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1038\/s41418-025-01639-9","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MEB is founder and part-owner of HMGBiotech\n                      \n                      . All other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The use of all human samples was approved by the ethical committee of IRCCS Ospedale San Raffaele. Name of the ethical approval: PREDICT MESO. All analyses were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}